Event dossier

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

0 reports0 sourcesMay 31, 2026, 12:00 PM
FilterEvent feed
Clustered coverageAll sources
Coverage timeline0
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

No linked coverage has been stored for this event yet.
Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.

El Psy Congroo